The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

According to a recent study, glucagon-like peptide-1 receptor agonists are associated with a reduction in alcohol intake.